Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Vritmeta 35 Trimetazidine Hydrochloride Tablets 35 mg
Vritmeta 35 Trimetazidine Hydrochloride Tablets 35 mg are specially formulated to assist individuals in managing angina pectoris. This medication works by enhancing the heart's metabolic function, making it an essential treatment for patients with chronic heart conditions.
Uses of Vritmeta 35 Trimetazidine Hydrochloride Tablets 35 mg
Vritmeta 35 Trimetazidine Hydrochloride Tablets 35 mg are primarily indicated for:
Angina Pectoris: Helps to prevent and manage the symptoms of chest pain due to coronary artery disease.
Adjunct Therapy: Often used alongside other treatments for heart conditions to improve overall cardiac function.
Benefits of Vritmeta 35 Trimetazidine Hydrochloride Tablets 35 mg
Reduced Angina Attacks: Decreases the frequency and severity of chest pain episodes.
Improved Cardiac Efficiency: Enhances the heart's energy metabolism, helping it to function more efficiently under stress.
Better Quality of Life: Patients often experience an improvement in physical performance and reduced limitations due to heart conditions.
Minimal Side Effects: Generally well-tolerated with a low incidence of adverse effects.
Supports Cardiovascular Health: Contributes to overall heart health by reducing the oxygen demand of cardiac cells.
Mechanism of Action of Vritmeta 35 Trimetazidine Hydrochloride Tablets 35 mg
Trimetazidine acts by:
Enhancing Glucose Utilization: Shifts the metabolism from fatty acid oxidation to glucose oxidation, which is more oxygen-efficient, thereby reducing the strain on the heart.
Protecting Cardiac Cells: Helps to preserve intracellular ATP levels and prevents the accumulation of toxic substances in the heart cells.
Improving Coronary Blood Flow: Aids in better blood flow within the coronary arteries, ensuring adequate oxygen supply to the heart muscles.